The FDA Oncologic Drug Advisory Committee meetings on Tuesday and Wednesday discussed therapies across lymphoma, multiple myeloma, bladder cancer, and prostate cancer.

This male cancer can be easily screened for, but the lack of symptoms in the early stages makes it easy to overlook.

Nubeqa was approved for a similar indication in the US last July, and will compete in the nmCRPC market with Janssen's Erleada (apalutamide) and Astellas/Pfizer's Xtandi (enzalutamide).